[Effect of the treatment of relapsing bronchitis in children with combined interferon preparations applicated by different methods].
The clinico-immunological effect and significance of the rectal and inhalation methods of the application of recombinant IFN-alpha2 with complex immunoglobulin preparation (CIP) in the treatment of relapsing bronchitis in children have been determined. The determination of the levels of interferon activity in buccal secretions and in venous blood permits the objective evaluation of the immune responsiveness of the body and the treatment effect. The immunocorrecting action of the combined immunobiological preparation (recombinant IFN-alpha2 and CIP) is manifested by an increased level of endogenic interferon and the stimulation of phagocytic activity.
Bashkina
O A
OA
Afanas'ev
S S
SS
Aleshkin
V A
VA
Vorob'ev
A A
AA
Rubal'skiĭ
O V
OV
Kokuev
A V
AV
Somova
E I
EI
D000280:Administration, Inhalation; D000285:Administration, Rectal; D000336:Aerosols / Q000627:therapeutic use; D029481:Bronchitis, Chronic / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage / Q000627:therapeutic use*; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D007372:Interferons / Q000032:analysis; D007958:Leukocyte Count; D008297:Male; D010586:Phagocytes / Q000276:immunology; D011994:Recombinant Proteins; D012463:Saliva / Q000276:immunology; D055502:Secondary Prevention; D013488:Suppositories / Q000627:therapeutic use
D000336:Aerosols; D007136:Immunoglobulins; D007370:Interferon Type I; D011994:Recombinant Proteins; D013488:Suppositories; D007372:Interferons